Abstract
Two-pore-domain (K2P) potassium channels mediate background potassium currents, stabilizing resting membrane potential and expediting action potential repolarization. In the heart, K2P3.1 (TASK-1) channels are implicated in the cardiac plateau current, I KP . Class III antiarrhythmic drugs target cardiac K+ currents, resulting in action potential prolongation and suppression of atrial and ventricular arrhythmias. The objective of this study was to investigate acute effects of the class III antiarrhythmic drug amiodarone on human K2P3.1 channels. Potassium currents were recorded from Xenopus oocytes using the two-microelectrode voltage clamp technique. Amiodarone produced concentration-dependent inhibition of hK2P3.1 currents (IC50 = 0.40 µM) with maximum current reduction of 58.1%. Open rectification properties that are characteristic to hK2P3.1 currents were not altered by amiodarone. Channels were blocked in open and closed states in reverse frequency-dependent manner. hK2P3.1 channel inhibition was voltage-independent at voltages between −40 and +60 mV. Modulation of protein kinase C activity by amiodarone does not contribute to hK2P3.1 current reduction, as pre-treatment with the protein kinase C inhibitor, staurosporine, did not affect amiodarone block. Amiodarone is an inhibitor of cardiac hK2P3.1 background channels. Amiodarone blockade of hK2P3.1 may cause prolongation of cardiac repolarization and action potential duration in patients with high individual plasma concentrations, possibly contributing to the antiarrhythmic efficacy of the class III drug.
Similar content being viewed by others
References
Backx PH, Marban E (1993) Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Circ Res 72:890–900
Barbuti A, Ishii S, Shimizu T, Robinson RB, Feinmark SJ (2002) Block of background K+ channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor. Am J Physiol 282:H2024–H2030
Bayliss DA, Sirois JE, Talley EM (2003) The TASK family: two-pore domain background K+ channels. Mol Interv 4:205–219
Besana A, Barbuti A, Tateyama MA, Symes AJ, Robinson RB, Feinmark SJ (2004) Activation of protein kinase Cε inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes. J Biol Chem 279:33154–33160
Duprat F, Lesage F, Fink M, Reyes R, Heurteaux C, Lazdunski M (1997) TASK, a human background K+ channel to sense external pH variations near physiological pH. EMBO J 16:5464–5471
Futamura Y (1996) Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes. J Toxicol Sci 21:125–134
Gierten J, Ficker E, Bloehs R, Schlömer K, Kathöfer S, Scholz E, Zitron E, Kiesecker C, Bauer A, Becker R, Katus HA, Karle CA, Thomas D (2008) Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol 154:1680–1690
Goldstein SAN, Bockenhauer D, O’Kelly I, Zilberberg N (2001) Potassium leak channels and the KCNK family two-P-domain subunits. Nat Rev Neurosci 2:175–184
Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC (1983) Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. Am Heart J 106:935–943
Hohnloser SH, Klingenheben T, Singh BN (1994) Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121:529–535
Honore E, Maingret F, Lazdunski M, Patel AJ (2002) An intracellular proton sensor commands lipid- and mechanogating of the K+ channel TREK-1. EMBO J 21:2968–2976
Kathöfer S, Thomas D, Karle CA (2005) The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 23:217–230
Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W (1999) Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359:212–219
Kindler CH, Yost CS, Gray AT (1999) Local anesthetic inhibition of baseline potassium channels with two pores in tandem. Anesthesiology 90:1092–1102
Lalevee N, Monier B, Senatore S, Perrin L, Semeriva M (2006) Control of cardiac rhythm by ORK1, a Drosophila two-pore domain potassium channel. Curr Biol 16:1502–1508
Latini R, Tognoni G, Kates RE (1984) Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 9:136–156
Leonoudakis D, Gray AT, Winegar BD, Kindler CH, Harada M, Taylor DM, Chavez RA, Forsayeth JR, Yost CS (1998) An open rectifier potassium channel with two pore domains in tandem cloned from rat cerebellum. J Neurosci 18:868–877
Lopes CMB, Gallagher PG, Buck ME, Butler MH, Goldstein SAN (2000) Proton block and voltage-gating are potassium-dependent in the cardiac leak channel Kcnk3. J Biol Chem 275:16969–16978
Maingret F, Patel AJ, Lazdunski M, Honore E (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. EMBO J 20:47–54
Marban E (2002) Cardiac channelopathies. Nature 415:213–218
Naccarelli GV, Wolbrette DL, Patel HM, Luck JC (2000) Amiodarone: clinical trials. Curr Opin Cardiol 15:64–72
Nerbonne JM, Kass RS (2005) Molecular physiology of cardiac repolarization. Physiol Rev 85:1205–1253
Patel A, Honore E (2001) Properties and regulation of mammalian 2P domain K+ channels. Trends Neurosci 24:339–346
Podrid PJ (1995) Amiodarone: reevaluation of an old drug. Ann Intern Med 122:689–700
Putzke C, Wemhöner K, Sachse FB, Rinne S, Schlichthörl G, Li XT, Jae L, Eckhardt I, Wischmeyer E, Wulf H, Preisig-Müller R, Daut J, Decher N (2007) The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res 75:59–68
Silver PJ, Connell MJ, Dillon KM, Cumiskey WR, Volberg WA, Ezrin AM (1989) Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents. Cardiovasc Drugs Ther 3:675–682
Sirois JE, Lei Q, Talley EM, Lynch C, Bayliss DA (2000) The TASK-1 two pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci 20:6347–6354
Thomas D, Zhang W, Karle CA, Kathöfer S, Schöls W, Kübler W, Kiehn J (1999) Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 274:27457–27462
Thomas D, Plant LD, Wilkens CM, McCrossan ZA, Goldstein SAN (2008) Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 58:859–870
Veronese ME, McLean S, Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol 26:721–731
Zimetbaum P (2007) Amiodarone for atrial fibrillation. N Engl J Med 356:935–941
Acknowledgments
We are grateful to Dr. Steve Goldstein for providing the cDNA clone encoding hK2P3.1. This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (project KA 1714/1-1 to C.K.), from the German Cardiac Society (Max Schaldach Research Scholarship to D.T.), from the University of Heidelberg (FRONTIERS program), from the ADUMED-Foundation (to D.T.), and from the National Institutes of Health (HL71789 to E.F.). J.G. is a fellow of the MD/PhD program at the University of Heidelberg.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gierten, J., Ficker, E., Bloehs, R. et al. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. Naunyn-Schmied Arch Pharmacol 381, 261–270 (2010). https://doi.org/10.1007/s00210-009-0454-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-009-0454-4